ArticleBMC cancer2012

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.

Alessandra Fabi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.